zopapogene imadenovec

AXP000159.1 · Cancer vaccine

Platform
gorilla adenovirus (AdenoVerse, non-replicating)
Originator
Precigen
Sponsor
Precigen

Names

NameTypeSource
zopapogene imadenovecpreferred name, INNcurator, ncit
Papzimeosbrandfda
zopapogene imadenovec-drbaUSANfda
PRGN-2012codencit
Gorilla-derived Adenovirus-expressing HPV-6/11 Vaccine PRGN-2012 ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
gorilla adenovirus
Replication
non replicating
Modifications
non-replicating gorilla adenovirus vector (AdenoVerse platform)
Transgenes
HPV-6 and HPV-11 antigens
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C207022
FDA UNII
C525BYS7TP

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2025-08-14approvedPapzimeosTreatment of adults with recurrent respiratory papillomatosissource

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07901738Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenNot yet recruitingPhase 32026-12-312029-0115Juvenile-onset Recurrent Respiratory Papillomatosis; Papillomavirus Infections; Recurrent Respiratory Papillomatosis (RRP)
NCT07756840Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingPhase 22026-11-182029-07-0150Human Papillomavirus (HPV); Laryngeal Diseases; Papillomavirus Infection; Respiratory Recurrent Papillomatosis (RRP); Respiratory Tract Neoplasm; Tracheal Diseases
NCT06538480Zopa Retreatment and Vector Shedding in Adults With RRPRecruitingPhase 42024-07-112027-12-0230Papillomaviridae; Papillomavirus Infection; Recurrent Respiratory Papillomatosis
NCT04724980Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisActive not recruitingPhase 1/22021-03-162024-06-0538Papillomaviridae; Papillomavirus Infections; Recurrent Respiratory Papillomatosis

Recent changes

SeenTrialChangeDetailTitle
2026-11-12NCT07901738new trialZopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39855244PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.The Lancet. Respiratory medicine2025name in title: PRGN-2012

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41205140Zopapogene Imadenovec: First Approval.Molecular diagnosis & therapy2026name in title: zopapogene imadenovec
PMID 41720607Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years.Journal for immunotherapy of cancer2026name in abstract: zopapogene imadenovec
PMID 42103572The Efficacy and Safety of Systemic Treatment for Managing Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-analysis.Journal of voice : official journal of the Voice Foundation2026name in abstract: zopapogene imadenovec-drba
PMID 42248643Non-replicating adenoviral vectors for cancer gene therapy.Advances in cancer research2026name in abstract: Papzimeos
PMID 42438380Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis.The Annals of pharmacotherapy2026name in title: zopapogene imadenovec-drba
PMID 40307073Disease Control and Voice Outcomes Following Treatment With PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis.Journal of voice : official journal of the Voice Foundation2025name in title: PRGN-2012
PMID 41020881Emerging Therapeutic Strategies for HPV-Related Cancers: From Gene Editing to Precision Oncology.Current issues in molecular biology2025name in abstract: PRGN-2012
PMID 41377441From surgery to immunotherapy: Papzimeos as the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP).Annals of medicine and surgery (2012)2025name in title: Papzimeos
PMID 37878675The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis.Science translational medicine2023name in abstract: PRGN-2012
PMID 34145272Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis.NPJ vaccines2021name in abstract: PRGN-2012

NIH grants

ProjectTitleOrganisationPIYearsLinked by
U01CA298630Cell-Cell Signaling Driving HPV-Induced Respiratory Disease and Vaccine ResponseCINCINNATI CHILDRENS HOSP MED CTRWELLS, SUSANNE I2025–2026name in abstract: PRGN-2012
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: PRGN-2012
ZIABC010666Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCIGULLEY, JAMES L.2009–2025name in abstract: PRGN-2012
ZIDDC000075NIDCD Core for Clinical Research and CareNATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSLEVY, JOSHUA2021–2025name in abstract: PRGN-2012
ZIABC010425Strategies for Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2009–2023name in abstract: PRGN-2012

Notes

PRGN-2012: non-replicating gorilla adenovirus expressing HPV 6 and HPV 11 antigens, given as four subcutaneous injections over 12 weeks. FDA approved 14 August 2025 as Papzimeos (STN 125832, proper name zopapogene imadenovec-drba) for recurrent respiratory papillomatosis in adults: the first approved therapy for that disease, and a full rather than accelerated approval. A therapeutic vaccine against an HPV-driven benign neoplasm; recorded here as a cancer vaccine. The exact gorilla adenovirus serotype of the AdenoVerse vector is not stated in the sources used.

How to cite

zopapogene imadenovec (AXP000159.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000159.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.